• Source: Efavirenz/lamivudine/tenofovir

Efavirenz/lamivudine/tenofovir (EFV/3TC/TDF), sold under the brand name Symfi among others, is a fixed-dose combination antiretroviral medication for the treatment of HIV/AIDS. It combines efavirenz, lamivudine, and tenofovir disoproxil. As of 2019, it is listed by the World Health Organization as an alternative first line option to dolutegravir/lamivudine/tenofovir. It is taken by mouth.
Side effects can include joint pain, sleepiness, headaches, depression, trouble sleeping, and itchiness. Severe side effects may include depression, psychosis, or osteonecrosis. In those with a history of epilepsy, it may increase the frequency of seizures. Greater care should also be taken in those with kidney problems. Its use during pregnancy appears to be unsafe.
It is on the World Health Organization's List of Essential Medicines. The combination received tentative approval in the United States in 2014, and was granted approval in February 2018. Its availability and importance is supported by Medecins Sans Frontieres. It is available as a generic medication.




References






External links


"Efavirenz". Drug Information Portal. U.S. National Library of Medicine.
"Lamivudine". Drug Information Portal. U.S. National Library of Medicine.
"Tenofovir disoproxil". Drug Information Portal. U.S. National Library of Medicine.
"Tenofovir disoproxil fumarate". Drug Information Portal. U.S. National Library of Medicine.

Kata Kunci Pencarian:

• Efavirenz/lamivudine/tenofovir
• Dolutegravir/lamivudine/tenofovir
• Efavirenz
• WHO Model List of Essential Medicines
• Emtricitabine/tenofovir
• Abacavir/dolutegravir/lamivudine
• Emtricitabine
• Cabotegravir/rilpivirine
• Dapivirine Ring
• Management of HIV/AIDS